Plasma Biomarker in Amblyopia Patients

Sun Yat-sen University

Status: Enrolling

Conditions: Amblyopia

Treatments: Procedure: standard amblyopia treatment

Study type: Observational

Funder types: Other

Identifiers

NCT05705778

2022KYPJ102

Details and patient eligibility

About

This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.

Enrollment: 600 estimated patients

Sex: All

Ages: 3 to 12 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Diagnosed with amblyopia
• 3-12 years of age
• Able to tolerate amblyopia treatment
• Agree to be involved in this study and agree to have a follow up visit every 3 months.

Exclusion criteria

• Have previous treatment history before
• Have pathological ocular anomalies known to cause reduced visual acuity
• Have previous psychiatric, visual or neurological disorders
• Have eccentric fixation and/or abnormal retinal correspondence
• Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves

Trial design

600 participants in 5 patient groups

Strabismic

Treatment:

Procedure: standard amblyopia treatment

Anisometropic

Treatment:

Procedure: standard amblyopia treatment

Isoametropic

Treatment:

Procedure: standard amblyopia treatment

Visual deprivation

Treatment:

Procedure: standard amblyopia treatment

Mixed group

Treatment:

Procedure: standard amblyopia treatment